Company Profile / Healthtech · AI
FORUS — formerly Tandem · New York, NY
Forus.
The AI network quietly rebuilding the plumbing between a doctor's prescription and a patient actually starting treatment.
The AI network quietly rebuilding the plumbing between a doctor's prescription and a patient actually starting treatment.
Nearly one in three prescriptions written in America is never filled. Not because the science failed, and usually not because the doctor and diagnosis were wrong - but because the paperwork in between broke down. Prior authorizations, appeals, enrollment forms, benefit checks, and pharmacy hand-offs pile up into weeks of faxes and phone calls. Forus, a New York healthtech company founded in 2023, exists to close that gap.
Forus runs an AI-powered network that connects doctors, pharmacies, payers, and biopharma. Embedded into physician workflows, it automates the steps between a clinical decision and a patient starting treatment: it determines the optimal approval pathway, generates and submits the prior-authorization forms, files appeals when needed, verifies benefits, matches patients to financial-assistance programs, and routes the prescription to the right pharmacy. Turnaround that used to be measured in weeks is measured in hours. The company's tagline puts the goal plainly - "accelerating medicine for the people."
The company was originally named Tandem (its legal entity is Tandem Technology, Inc.), and some older security and social handles still carry the Tandem name. The rebrand to Forus reads like a thesis said out loud: infrastructure for us - the patients and providers waiting on a medicine that was already approved.
“Too few drugs make it to market and too few eligible patients receive treatment. Science should be the only limit to medicine.”
A provider writes the prescription inside their existing EHR.
Forus picks the optimal pathway and files prior-auth forms.
A real-time dashboard monitors every step of approval.
Patients get proactive status on approval and fulfillment.
The Rx is routed to the right pharmacy - in hours.
Sources: forus.com, Accel, Forbes (2026). Turnaround figures are company-disclosed.
The prescription-to-fulfillment process is a maze of forms, faxes, and phone calls that delays medications for weeks or months even when the doctor, diagnosis, and drug are all correct. Doctors lose hours a week to administrative work; patients give up at the pharmacy counter. Forus removes that busywork and gives both sides visibility into where a prescription actually stands.
Thousands of medical practices and health systems use Forus - across dermatology, rheumatology, gastroenterology, allergy, and specialty care - alongside patients, who use it for free. On the paying side, five of the top 10 global pharmaceutical companies are partners. Much of the growth has come from doctors telling other doctors, not a heavy sales push.
Most software charges its user. Forus flips the model: it is free for doctors and patients, and it is paid for by pharmaceutical companies, who benefit when more eligible patients successfully start and stay on approved therapies. The incentives finally line up around access.
Accel describes Forus as an "AI 2.0" company - architected around commoditized intelligence rather than one proprietary model. Every processed prescription improves the network and yields insight into how treatment actually flows, which in turn helps pharma understand where therapies reach patients and where they stall.
Annualized revenue is company-disclosed and approximate; roughly 5x growth reported in early 2026.
Auto-generates and submits PA forms from the EHR and selects the optimal approval pathway.
Checks insurance coverage and eligibility in real time before treatment begins.
Drafts and files appeals when authorizations are denied, cutting manual back-and-forth.
Completes and routes manufacturer and program enrollment for specialty therapies.
Routes prescriptions to the right retail or specialty pharmacy and coordinates fulfillment.
Matches patients to copay and financial-assistance programs to lower out-of-pocket cost.
Forus sits at the operational center of medication access - between prescribers, payers, pharmacies, and drug makers. Its main competition is the status quo: faxes, phone calls, and in-house administrative staff, plus legacy hub-services vendors and other prior-authorization automation players such as CoverMyMeds and Cohere Health. The distinction Forus leans on is the network: it is free to providers and patients, it spans every drug, payer, and pharmacy, and each prescription it processes compounds into better routing and sharper data.
Investors frame the bet as a shift from selling software to running healthcare orchestration. As Accel put it in explaining its Series B lead, the goal is "building the foundation for modern medicine."
Sahir Jaggi, 31, is Forus's CEO and founder. He studied biomedical engineering at Columbia University and spent roughly six years at the health insurer Oscar, rising to a product-strategy leadership role - a front-row seat to the administrative machine he later set out to automate. He has also been associated with early-stage investing through Rough Draft Ventures, and in 2025 was named to the Forbes 30 Under 30 Healthcare list. Forus's team blends engineers, AI researchers, and healthcare veterans.
“We started Forus to build the foundation for modern medicine.”
Sahir Jaggi starts the company (as Tandem) to automate the administrative backend of prescriptions.
Prior auth, appeals, enrollment, pharmacy routing, and affordability come together in one system.
Jaggi is recognized on the Healthcare list as adoption spreads by word-of-mouth among doctors.
A $123M Series B led by Accel, with Thrive Capital and General Catalyst, values Forus at $1 billion.